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Abstract
Objective: The 2006 Research Forum addressed the goal of formulating a research agenda for early-onset bipolar
disorder (EOBP) and improving outcome by understanding the risk and protective factors that contribute to its
severity and chronicity.
Method: Five work groups outlined barriers and research gaps in EOBP genetics, neuroimaging, prodromes,
psychosocial factors, and pharmacotherapy.
Results: There was agreement that the lack of consensus on the definition and diagnosis of EOBP is the primary
barrier to advancing research in BP in children and adolescents. Related issues included: the difficulties in man-
aging co-morbidity both statistically and clinically; acquiring adequate sample sizes to study the genetics, biology,
and treatment; understanding the EOBP’s developmental aspects; and identifying environmental mediators and
moderators of risk and protection. Similarly, both psychosocial and medication treatment strategies for children
with BP are hamstrung by diagnostic issues. To advance the research in EOBP, both training and funding mech-
anisms need to be developed with these issues in mind.
Conclusions: EOBP constitutes a significant public health concern. Barriers are significant but identifiable and thus
are not insurmountable. To advance the understanding of EOBP, the field must be committed to resolving diag-
nostic and assessment issues. Once achieved, with adequate personnel and funding resources, research into the
field of EOBP will doubtless be advanced at a rapid pace.
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Introduction
The main objective of the American Academy of Childand Adolescent Psychiatry’s Research Forum is to drive
the research policy agenda for child and adolescent psychia-
try. The 2006 Research Forum was presented with the goal of
addressing a research agenda for bipolar disorder (BP) in
youths, emphasizing how to improve outcome by under-
standing the risk and protective factors that contribute to its
severity and chronicity.
By all recent accounts, child- and young adolescent-onset
bipolar spectrum disorder is a significantly impairing condi-
tion that severely disrupts the lives of those afflicted and their
families (Pavuluri et al. 2005). Although research on this sub-
ject has increased enormously in recent years, we are a long
way from knowing how to prevent BP, and our treatments
have modest effects at best (see Goodwin and Jamison 2007,
pp. 907ff for review). Unfortunately, goals such as treatment
and prevention are dependent upon first understanding
how to identify cases to be studied. Thus, the primary goal of
the research agenda is to refine the multiple definitions of
child- and adolescent-onset BP that have been reported in the
literature. Clarifying how to identify, describe, assess, and
diagnose cases of early-onset bipolar disorder (EOBP) will
greatly enhance our ability to meet the rest of the research
agenda.
As it was the intention of the forum that lessons about risk
factors, co-morbidity, intervention, and prevention may shed
light on strategies for research in EOBP, the committee spent a
good deal of time reviewing the literature on risk factors,
developmental course, and treatments in conditions that of-
ten co-occur in children with early-onset BP (e.g., attention-
deficit=hyperactivity disorder [ADHD], oppositional defiant
disorder [ODD], and major depressive disorder [MDD]). In
addition, the committee reviewedmethods of developmental,
genetic, and neuroimaging studies of these other disorders,
again to determine if useful methods, approaches, and strat-
egies could be used to study the children who suffer the
complex psychopathology described as EOBP.
Thus, after a reviewofwhat is knownabout BP inyouth,what
is known about risk and protective factors in ADHD, ODD,
and MDD, and what has been done in genetics and neuroima-
ging in other disorders, thework groups dividedup todevelop a
strategy on how best to advance the field of study of EOBP.
Methods
Five workgroups were charged with identifying hurdles in
important domains to be surmounted so that research on the
etiology and prevention of EOBP can be conducted. These
domains were: genetics (because of the high heritability of the
disorder), neuroimaging (because of its promise of providing
insights into the biology of the illness), pharmacotherapy (be-
cause of its importance to intervention), prodromes (because of
the need to understand very early manifestations of illness
and the potential for prevention), and psychosocial factors
(because of their impact on illness emergence, persistence and
treatment response). Recommendations were also solicited.
Results
There were many overlaps to the perceived barriers inter-
fering with research progress. These overlaps and our re-
commendations have been summarized and synthesized
below and in the discussion.
Topic #1: Definition and assessment of BP
The biggest and most consistently agreed upon barrier for
progress in research on BP in children and adolescents re-
mains the lack of consensus regarding the definition, ascer-
tainment, and even the name of the disorder (Goodwin and
Jamison 2007). There is increasing agreement that EOBP exists.
The current debate focuses on how frequently it occurs, and
whether bipolar spectrum disorders are the appropriate di-
agnostic home for seriously impaired children who have se-
vere aggression, problemswith hyperactivity, impulsivity and
inattention, andmood instability. There is disagreement about
whether these mood-dysregulated children meet narrow
Diagnostic and Statistical Manual of Mental Disorders, 4th edition
(DSM-IV) (American Psychiatric Association 1994) criteria or
would meet narrow criteria if criteria were modified, if chil-
dren have a particular bipolar subtype, or they have one of
many conditions that may present with aggression, inatten-
tion and mood instability. We have arrived at the controversy
for several reasons: (1) DSM favored cross-sectional symp-
toms over history (Andreasen 2007); (2) neither insurers, the
Food and Drug Administration (FDA) (for treatment studies)
nor funding agencies want to contend with diagnostic ambi-
guity; (3) DSM-created co-morbidity but not a way to re-
assemble multiple disorders to define subgroups of children;
(4) impulsive, affective aggression has been difficult to classify
(Connor 2002). Reframed as mood instability, it is no less
complicated. Unfortunately, fitting what is likely a multitude
of childhood disorders into one diagnostic category originally
developed for the study of adult BP remains unsatisfactory at
best and destructive at worst. It is destructive both because we
do not know which children are being described and thus do
not know how to understand research findings, and because
the valid scientific questions that have arisen have been
framed in ways that cast doubt on the entire profession.
1. Barriers. Barriers begin with lack of agreement about
how to name children being described in publications. In-
consistently referred to as pediatric or juvenile BP, juvenile or
pediatric mania, prepubertal and pubertal BP, or narrow=
intermediate=broad phenotype, these names may or may not
refer to the same exact condition, and may or may not refer to
children with more generic mood dysregulation. For consis-
tency, we will use the term EOBP to refer to onset of mania at
18 years, and very-early-onset (VEOBP) to onset of mania at
12 years of age. The term ‘‘bipolar’’ may refer to the entire
spectrum, so some studies include BP I, II, and not otherwise
specified (NOS), or to the acute manic episode itself. Studies
do not always clarify if subjects are acutely ill at the time of
assessment, manic or hypomanic (a severity dimension), or if
lifetime mania is being ascertained while the patient is eu-
thymic or depressed. The distinction between levels of se-
verity or between current and lifetime mania is important to
understanding results of biological studies. For instance, se-
verity of illness impacts treatment outcome in ADHD (Hin-
shaw 2007) and depression (Curry et al. 2006).
2. Operationalizing criteria. Although structured or
semistructured interviews are used to establish diagnoses,
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researchers differ on how they elicit, assess, characterize, and
count criteria (Youngstrom et al. 2006). The degree to which
these decisions influence their sample selection and ultimate
findings is unclear (Galanter et al. 2008). There is, as yet, no
‘‘right or wrong’’ about the various approaches—only that the
end result means that sample A may sound superficially like
sample B (i.e., both have ‘‘BP’’), but may contain people who
would not be included in sample B.
Classic manic depression, as described by Goodwin and
Jamison (2007) (pp. 29–87) is apparently very uncommon in
VEOBP (Harrington andMyatt 2003). As the boundaries of BP
have broadened, the symptoms and diagnosis have become
more common in both youth and adults (Biederman et al.
2004; Hirschfeld and Vornik 2004).
Investigators disagree about the necessity for euphoria or
grandiosity to be present (Geller et al. 2002; Leibenluft et al.
2003). Some feel that severe irritability=explosiveness is the
defining feature of VEOBP (Mick et al. 2005). Research on the
taxonomy of irritability is clearly needed. It is important to
distinguish the level of reactivity inherent in the definition of
irritability from the subsequent response. The development of
psychometrically valid scales for irritability separate from
those designed to measure aggression and mania would fa-
cilitate etiologic as well as treatment research ( Jensen et al.
2007).
3. Episodes. In acute mania, the relative rapidity of
change from premorbid functioning helps make clear an epi-
sode’s onset. Return to a premorbid level of functioning with
very mild or no symptoms defines the offset. Without a clear
onset and offset, disentangling episode onset from develop-
mental shifts (onset of particularly terrible twos or threes,
stressful transitions to school in a child with other problems),
or defining ‘‘stable baseline’’ in someone who is still very
young may be difficult. There are several questions that arise
about episodes. One is how long symptoms need to co-occur
to have predictive validity for future BP. Some young people
with classic manic symptoms that may last for less than 4 days
and subsequently develop full BP I or BP II (Birmaher et al.
submitted). Another is whether EOBP is exclusively an epi-
sodic illness (narrow-phenotype BP) or whether it also en-
compasses nonepisodic deficits in emotion regulation (e.g.,
severemooddysregulation). The intramuralNational Institute
of Mental Health (NIMH) bipolar program is attempting to
address that question (Leibenluft et al. 2003) with longitudinal
studies (e.g., Brotman et al. 2006), family history research (e.g.,
Brotman et al. 2007), and specific studies of brain mechanisms
(e.g., studies of the impact of reward, punishment, and frus-
tration on attention in pediatric BP) (Rich et al. 2007).
4. Pervasiveness of symptoms. Both DSM-III=IV and
the International Statistical Classification of Diseases, 10th
revision (ICD 10) recognize the need for ADHD symptoms
or some impairment to be present in more than one setting;
ICD 10 requires the full disorder in two settings. There is no
such consideration for mania because the symptoms were
developed from pervasively ill adults, usually hospitalized
(Goodwin and Jamison 2007, pp. 89–115). A condition that
occurs in only one setting likely differs from one that is per-
vasive. A child with less severe hypomania may be more
situationally contained than one with psychotic mania. A
different disorder, anxiety, may cause a child to behavewell at
school because s=he is self-conscious and be subsequently
symptomatic at home where s=he is comfortable. The impli-
cations of manic symptoms in only one setting clearly need
further research to determine, among other things, whether
inconsistent observations across settings rule out the diag-
nosis of mania or imply a less severe condition.
5. Information variance. Parents are always interviewed,
but some researchers only interview children over age 12;
others interview all youths. However, it is not always stated
whether criteria are met by symptoms from parent, from
child, some from each (the ‘‘OR’’ rule), requires both parent
and child to agree (the ‘‘AND’’ rule), or uses parent-only in-
formation if there is disagreement. Decisions about infor-
mants need more than a simplistic ‘‘and=or’’ rule (Kraemer
et al. 2003). In genetic studies, heritability estimates in chil-
dren may change depending on informant source (Thapar
and Rice 2006).
6. Long-term stability of diagnosis in VEOBP. If a life-
timemanic or hypomanic episode is endorsed at one time and
not another, it is assumed that its presence is the accurate
report. Yet both false-positive and false-negative reports are
problematic.Mildepisodesmaybemissed(Kendleretal.2001),
but recall may not accurately distinguish manic symptoms
from co-morbid symptoms of anxiety, agitation, or ADHD.
Although there are adult studies of longitudinal reliability
of major depression (Kendler et al. 2001) and psychosis
(Schwartz et al. 2000), diagnosis and stability of diagnosis of
mania or hypomania over more than a year or two has barely
been explored in adults (Fraguas et al. 2008; Ruggero et al.,
2009) let alone in children and adolescents. A further potential
confound occurs when informants change from parent to
offspring.
Topic #2: Managing co-morbidity
Co-morbidity, whether it represents true co-occurrence of
disorder or is a sign of illness severity, complicates treatment
and outcome (Carlson et al. 2002; Consoli et al. 2007). For EOBP,
common co-morbid disorders include ADHD and ODD=
conduct disorder (CD), anxiety disorders, and, in teens, sub-
stance abuse. Other possible co-morbidities, like autism spec-
trum disorders, or disorders co-morbid with ADHD, like
learning and language disorders, are not usually assessed (Co-
hen et al. 1989; Carlson and Meyer 2006). Some conditions that
may occur, like those involving sensory integration or social
skills deficits, have no DSM label and therefore have no way of
even being coded. Co-morbidities, whether identified or not,
undoubtedly affect outcome (Carlson et al. 2002; Lahey 2008).
Handling co-morbidities is challenging. Ascertaining the
presence of another condition is addressed differently by
different research groups. For instance, some researchers may
count the same symptom (e.g., hyperactivity) toward both
ADHD and mania. Others specify that hyperactivity can
count toward the diagnosis of mania only if it begins (or
worsens over a baseline level) at the same time as the change
in mood. Another point of inconsistency between research
groups is whether to even consider a condition co-morbid
unless it is present only when the youth is euthymic.
Inclusion of a co-morbid disorder requires decisions about
how to account in the data analysis not just for the specific
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disorder but also for the cumulative impact and increased
severity that co-morbidities confer on outcome in general and
treatment in particular (Curry et al. 2006; Consoli et al. 2007;
Hinshaw 2007). In addition, each co-morbidity has its own
neurobiology, genetics, and level of severity. However, ex-
clusion of co-morbid disorders limits the ecological validity of
studies, not to mention the sheer difficulty of finding children
without a comorbid disorder.
Topic #3: Acquisition of adequate sample sizes
A barrier to understanding EOBP, its neuroscience (in-
cluding imaging and neuropsychological studies), treatment
(psychopharmacologic and psychosocial), and outcome is
acquiring adequate sample size. The narrower the definition
of EOBP that is used, the longer it takes to collect a reasonable
number of patients to study. However, in the absence of a
good sample description, unacknowledged heterogeneity is
introduced. Depending on the nature of the study, this is more
or less important. Certain phenotypes used in genetic studies
(e.g., the Child Behavior Checklist–juvenile=pediatric bipolar
phenotype) (Biederman et al. 1995) lend themselves to easy
definition and identification and have yielded important
findings in terms of heritability (Althoff et al. 2006), but rele-
vance to BP has not been consistently demonstrated (Meyer
et al. 2008; Volk and Todd 2007).
Topic #4: Standardization of measures across sites
One approach to collecting large samples is the perfor-
mance of multisite studies. These raise important issues with
regard to standardizing measures across sites. Reliability of
interviews and rating scales is possible within and across
groups, and some important multisite studies are already
underway. Especially careful consideration needs to be given
in the design of multi-site neuroimaging studies. There
are numerous potential sources of variability across sites that
need to be taken into account which include magnetic
resonance imaging (MRI) data acquisition (e.g., scanner
manufacturer, field strength, sequence specifications), pre-
processing (e.g., preprocessing software, parameters, nor-
malization templates), analysis tools (e.g., investigator
preference for use of widely available software such as
statistical parametric mapping [SPM], http:==www.fil.ion
.ucl.ac.uk=spm=; FSL, http:==www.fmrib.ox.ac.uk=fsl=; or
Freesurfer, www.nmr.mgh.harvard.edu=freesurfer=, or site-
specific home-grown software) and performance of software
operators (e.g. in anatomical determinations such as in region-
of-interest delineations). Testing of reliability across sites is
recommended but is labor intensive.
Topic #5: Developmental psychopathology
Understanding symptoms of EOBP requires understand-
ing the development of: (1) emotion regulation (which is rel-
evant to our understanding of mood lability, mood ‘‘swings’’,
pathological euphoria and irritability) (Cole and Hall 2008);
(2) reality testing (which is relevant to the concept of grandi-
osity) (Caplan et al. 2000); (3) temperament (which, like co-
morbidity, is likely to interact with, and depending on the
temperament, worsen the disorder) (Rutter et al. 2006; Klein
et al. 2008; Lahey 2008); (4) social cognition and language
development that is, receptive, expressive and pragmatic
(which impacts both outcome) (Lahey 2008) and accuracy of
reporting symptoms that require meta-cognitive ability.
Imaging researchers are increasingly incorporating neuro-
developmental perspectives into studies of BP. These have led
to recent advances in the identification of limbic regions in-
volved in EOBP, and research designed to identify continui-
ties and discontinuities in the involvement of limbic circuitry
in pediatric and adult presentations of BP (DelBello et al. 2004;
Frazier et al. 2005; Blumberg et al. 2006; Rich et al. 2006; Pa-
vuluri et al. 2007). Puberty plays an important role in brain
development (Blakemore and Choudhury 2006) and is asso-
ciated with a dramatic increase in rates of depression and
schizophrenia; however, there has been a paucity of research
investigating the role of puberty in BP. Future investigations
that address peripubertal brain changes and neurodevelop-
mental trajectories in girls and boys associated with the
emergence of bipolar symptoms may be pivotal in our un-
derstanding of the pathophysiology of the disorder.
Topic #6: Identifying children at risk
and the need for longitudinal studies
Affective and behavioral symptoms in children at familial
risk for BP may portend significantly impairing BP I (Lapalme
et al. 1997; Hillegers et al. 2005; Meyer et al. 2006; Duffy et al.
2007). However, these nonspecific symptoms may be on the
bipolar spectrum, harbingers of other behavior disorders sep-
arate from or co-morbid with BP, or transient developmental
deviations from the norm. As with most dimensions, the
boundaries between the upper limit of normal and early dis-
order are muddy. Moreover, if schizophrenia is any example,
many years elapse between the onset of nonspecific behavioral
disturbance, development of idiosyncratic thoughts and per-
ceptions, and ultimate psychosis (Maziade et al. 1996). The
relationship of behavioral symptoms and the eventual de-
velopment of psychosis are much more easily demonstrated
retrospectively than prospectively. To delineate a bipolar pro-
drome clearly, then, a key first step is agreeing on the actual
disorder, then on what its prodrome is, then who among
children at risk has the prodrome, and finally who of these
progresses to final disorder, versus remits, versus remains
subthreshold but symptomatic (Correll et al. 2007). To do that,
longitudinal studies of high-risk youth will be necessary.
Topic #7: Psychosocial risk factors
Concepts from developmental psychopathology (Cicchetti
1984; Rutter et al. 2006) have drawn increasing attention to
the early origins of risk for depression, including studies of
children of depressed parents. An emphasis on the unfolding
of critical developmental tasks, the interplay between organ-
ism and environment, and the effects of earlier adaptations
and dysfunctions on later development, have informed our
understanding of recurrent depression as largely a disorder
of early onset accompanied by multiple failures of adaptive
learning or maladaptive transactions among personal bio-
psychosocial vulnerabilities and environmental adversities
(Costello et al. 2002; Kendler et al. 2006). Earlier adaptive
difficulties portend later cognitive, school, and social mal-
adjustment, typically leading to greater levels of symptom-
atology, in a pernicious cascade of interacting factors
including, possibly, poorer response to treatment (Curry et al.
2006).
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Similarly, there are suggestions that life events, cognitive
vulnerability, the cognitive vulnerability-stress combination,
poor parenting, and maltreatment play a role in the onset and
course of EOBP (Alloy et al. 2005). Low socioeconomic status
(SES), stressful life events, cognitive style, negative, hostile
parenting as reflected in low maternal warmth, poor social
supports, parent divorce and conflict, low levels of family
cohesion and organization, increased family conflict, and
physical and sexual abuse have all been identified as risk
factors for development or exacerbation of EOBP (Leverich
et al. 2002; Tillman et al. 2003; Alloy et al. 2005; Birmaher et al.
2006; Kim et al. 2007). Other negative course indicators in-
clude rapid cycling, suicidal behavior, and high rates of co-
morbidity (Leverich et al. 2002). Insecure attachment is a risk
factor for emotional dysregulation and externalizing disor-
ders among offspring of parents with BP (Zahn-Waxler et al.
1988; Speltz et al. 1999; Shaw et al. 2001). Prenatal risk factors,
including exposure to prescribed medications (Pavuluri et al.
2006) and nonprescribed substances (O’Connor et al. 2002),
may be important predictors of EOBP.
Although there has been increased interest in nongenetic
contributions to BP,muchmorework is needed to understand
complex environmental risk and protective factors and their
interaction with genetic risk (Meyer et al. 2004; Moffitt et al.
2005). Multiinformant measures and methodology that allow
disentangling the impact of various psychosocial measures on
severity and co-morbidity versus a specific impact on BP will
be needed.
Topic #8: Genetics
Both BP and its age of onset appear to be influenced by
genetics (Faraone et al. 2004; Althoff et al. 2005), and while
considerable research has focused on genetic contributions to
the adult-onset phenotype, little is known about the genetic,
environmental, gene–gene, or gene–environment interaction
influences on EOBP. Behavioral genetic data and molecular
genetic studies to date support both genetic and environ-
mental contributions to EOBP (Geller et al. 2006). BP is familial
(Geller et al. 2006; Hirshfeld-Becker et al. 2006; Brotman et al.
2007; Rende et al. 2007), and considerable research has focused
on genetic risk factors for BP in adults (Hayden and Nurn-
berger 2006). Far less genetic research has been done on EOBP.
Of the strategies available to the psychiatric geneticist (family
studies, twin studies, adoption studies, whole genome asso-
ciation, methylation, or copy number variation, linkage, and
simple association studies), the majority of studies to date
have been family studies. These reveal that early-onset psy-
chopathology (ADHD, ODD, CD, MDD and EOBP) is more
common in offspring of parents with BP. It has also been
shown that some but not most children with suggestive bi-
polar symptoms grow up to have adult BP, although far more
have a wide variety of other psychopathologies (Meyer et al.
2008). Twin studies of ‘markers’ of EOBP indicate that the
broadly defined condition is different from other common
psychopathologies (Hudziak et al. 2005). Of the fourmolecular
genetic studies in EOBP probands, one found an association
with the val66 allele of the brain-derived neurotrophic factor
(BDNF) gene (Geller et al. 2004a), while another found evi-
dence of linkage to chromosome 9q34 (Faraone et al. 2006).
Hampering progress in genetics, not surprisingly, is the
lack of a clearly defined, replicable phenotype. Certain forms
of genetic studies require very large sample sizes (ideally, in
the thousands), thus multisite studies are essential and will
require common criteria and assessment techniques, so that
large samples can be collected from multiple sites.
Topic #9: Need for treatment studies
and predictors of response
Data suggest that, compared to those in adults, episodes of
mania and depression in youth are more protracted, and
mood is less stable even within an episode of mania or de-
pression, both of which contribute to poor prognosis (Geller
et al. 2004b; Birmaher et al. 2006). High rates of co-morbidity
with conditions that themselves have poor prognoses (e.g.,
ADHD with co-morbid oppositional-defiant or conduct dis-
order) confer a poor outcome (Lahey 2008). We need more
effective medications and treatment strategies to treat mania
and depression and prevent relapse to forestall this outcome.
Difficulty acquiring large enough homogeneous samples to
demonstrate efficacy and examine response predictor as well
as lack of a uniform approach to co-morbidity are problems.
Negative publicity surrounding clinical research in general
hampers public support. Retention in short-term pediatric
trials has been adequate, but could be better. Retention in
longer-term treatment trials is perhaps understandably
worse.
There are substantive gaps between the ideal development
of a drug as a treatment for a condition and what currently is
occurring in the field of EOBP, including:
1. Determining the appropriate doses of medication: This
requires knowledge of the biodisposition of a drug (Kearns
et al. 2003). Failure to determine appropriate dosing strategies
adequately can influence the outcome of medication treat-
ments (Findling 2004).
2. Identifying a therapeutic window from minimally ef-
fective to maximally tolerated: This is generally accomplished
by performing prospective studies in youth with the disease
entity in question, that examine safety and tolerability of
different dosing strategies. These studies must identify the
right starting dose, the rate of upward dose titration (if it is
necessary to achieve a target dose), and the therapeutic dose
range. Unfortunately, these fundamental pharmacological
parameters are oftentimes not identified in youth prior to the
conduct of definitive placebo controlled trials.
3. The results of safety and efficacy studies in youth are not
available to inform their treatment until several years after
they are marketed for adults.
4. Many youths will receive drug therapy for a protracted
period of time. Studies that examine these agents’ long-term
safety and effectiveness need to be conducted.
There are other key areas of unmet need for treatment re-
search in general:
1. There are key unstudied patient populations, including
children younger than 10 and patients who have bipolar
spectrum conditions.
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2. Patients with EOBP with substantive co-morbidities of-
ten are not enrolled in clinical trials. Moreover, the co-morbid
conditions themselves need treatment.
3. The sheer number of family=environment=
developmental factors important in other disorders means
that nonmedication strategies will be needed and need to be
studied along with medication interventions (Pavuluri et al.
2004; Fristad 2006; Miklowitz 2008). In adults with BP, these
controlled nonpharmacologic interventions are demonstrat-
ing success in increasing medication adherence and increas-
ing time before the next relapse.
4. Both the Multimodal Treatment Study of Children with
ADHD (MTA) and Treatment for Adolescents with Depres-
sion Study (TADS) trials found important moderators and
mediators of favorable treatment response (Curry et al. 2006;
Hinshaw 2007). In essence, these consisted basically of less
severe and less complicated illness and better-functioning
families. These are also predictors of better outcomes in EOBP
in general, as noted earlier, but should be examined with re-
spect to treatment response as well.
5. Pharmacogenomic studies that can examine genetic
mediators of both treatment response and adverse events are
needed.
6. Incorporating neuroimaging techniques into treatment
research may be able to provide useful insights (DelBello et al.
2006; Moore et al. 2007). The effects of interventions on the
brain can be evaluated using several neuroimaging ap-
proaches: (a) comparing subjects taking medications to those
who are not; (b) combining neuroimaging studies with
treatment trials to assess neurobiological predictors of indi-
vidual treatment response; and (c) assessing children treated
acutely and longitudinally to ascertain immediate and chronic
medication effects.
Topic #10: Lack of research funding
and people to do the research
Every condition has advocates clamoring for more gov-
ernment research dollars. To advance the needed research
agenda, EOBP will need this as well. There is a shortage of
people equipped to do the research. Focused and dedicated
support from stakeholders, such as those who have worked
successfully in autism research, is needed for this condition.
Recommendations
1. Adequate characterization of the heterogeneous group
of children who are significantly impaired with mood related
problems might be achieved in several ways:
(a) Convening one or several reconciliation meetings with
the goal of arriving at inclusive definitions and assessment
techniques, information to be solicited beyond symptom cri-
teria, and from whom to obtain the information. In conjunc-
tion with this, a glossary would be compiled that would
clearly operationalize symptoms such as irritability, euphoria,
and grandiosity, which can be difficult to elicit accurately and
diagnose in a developmentally and gender-sensitive fashion.
A reconciliation approach would allow all research groups
to understand where different phenotypic definitions fit into
the broader picture. What has complicated work up to now is
that investigators say they are using the same criteria, meth-
ods, and terms but use and define them differently (Young-
strom et al. 2006).
(b) In addition, research groups would provide informa-
tion, perhaps using the ‘‘article-plus’’ format, or in a publicly
available website, in much greater detail than is usually de-
scribed in scientific journals about the specific methods em-
ployed in their studies. This would entail not only worded
descriptions but also taped material to disclose how certain
patient responses to questions were interpreted or how cer-
tain diagnostic decisions were made. This could facilitate the
interpretation of scientific results generated from different
research groups and could help provide insights regarding
why between-site differences in study results sometimes oc-
cur. The difference between a reconciliation and a consensus
conference is that differences are highlighted and allowed in
the former as long as they are operationalized and identified.
(c) When significant differences in conceptualization of
ADHD were found between the United States and United
Kingdom, a study was organized using case material rated by
experts in both countries to determine where the source of
invariance arose (Prendergast et al. 1988). A recent, limited
version of that study done on children with manic symptoms
indicated similar discrepancies in how information was in-
terpreted (Dubicka et al. 2008). A more extensive study to
illustrate discrepancies and refine ways of eliminating them
might be useful.
2. The need for multisite=collaborative endeavors. Multi-
site studies can facilitate enrollment of larger sample sizes
than are generally feasible in single-site studies, increasing
statistical power. However, harmonization of ascertainment
and assessment is mandatory for multisite studies. Formation
of a treatment outcome network for EOBP similar to the adult
Systematic Treatment Enhancement Program for Bipolar
Disorder (STEP-BP program) (Sachs et al. 2003) is another
approach that would allow collection of longitudinal, natu-
ralistic data about effectiveness and tolerability of treatment.
3. Sample selection. Recognizing the heterogeneity of
children with mood dysregulation, it would be informative to
include for longitudinal study a group of youth with mood
dysregulation and manic symptomatology and patients
demonstrating specific expressions of bipolarity. Such a study
could clarify how greater or lesser degrees of specificity im-
pact outcome or are affected by development, co-morbidity,
and the like.
4. Treatment studies. The FDA has limited industry-
sponsored treatment studies to people with definable diag-
noses. Studies are needed of childrenwith explosive behavior.
One possibility would be to use groups of children with
ADHD and co-morbid ODD=CD with levels of explosive
behavior similar to that of bipolar spectrum youths to clarify
similarities and differences in treatment responses.
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Brain imaging and other neurobiological studies, including
pharmacogenomic studies, should be added to treatment
studies so that preliminary data regarding treatment response
and adverse events would be available from those studies as
well. Where existing treatment studies have used the same
methodology, samples could be combined to increase power
and examine response predictors.
5. Genetic studies. Longitudinal twin and sib-pair studies
can be used to study potential protective factors (e.g., family
cohesion, peer relations) and novel risk factors (e.g., being
bullied, birth season). In addition, pathophysiological family
studies designed to identify endophenotypes can facilitate
molecular genetic studies. Such studies can combine neuroi-
maging and genetic techniques.
Assuming that some type of nosologic reconciliation can
occur, new techniques on large singleton, twin, and family
samples can be applied to EOBP. In recent months, whole-
genome association, methylation, and copy number variation
approaches have yielded exciting results in other complex
disorders (diabetes, autism, etc.) and may offer promise in
studies of EOBP. Additional strategies, such as the use of
monozygotic twin pairs discordant for EOBP and offspring
of twin designs, offer added new frontiers for inquiry. Each of
these approaches will still depend on a clear taxonomic
strategy.
6. Fiscal implications. Studies that include large number of
subjects, multiple investigative sites, and longitudinal design
will require specifically targeted Requests for Applications
(RFAs) as well as new funding mechanisms and initiatives.
Training grants to focus specifically on developing more in-
vestigators in the field of EOBP will increase the probability
that key questions about EOBP may be answered. Combined
private and government philanthropy, such as the relatively
recently organized annual Pediatric Bipolar Conference, has
been helpful in stimulating young investigators.
Given that the extent of bipolar spectrum disorders in
adults is upwards of 4% (Merikangas et al. 2007), and that it is
an early-onset and genetic disorder, then it is incumbent on us
to find ways of diagnosing it early and preventing its pro-
gression. It is the hope of the Research Forum contributors
that some of the deliberations will facilitate progress toward
that end.
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